‎Almoosa Health: Q3 Loss Driven by Non-Cash Accounting Impact; Core Operations Remain Profitable

Logo Design of Almoosa Health Company

Almoosa Health Company reported a non-cash loss of SAR 81.9 million in the 3rd quarter of 2026, arising from the mark-to-market (MTM)appraisal of its profit-rate hedging agreements, adding to a reported bottom line of SAR 31.8 million for the quarter.

The Company discussed that rate of interest in Saudi Arabia increased once again in September 2026 in the middle of more comprehensive worldwide interest-rate motions and inflationary pressures related to geopolitical and macroeconomic obstacles. Under relevant accounting requirements, monetary acquired agreements should be revalued at dominating market rates on a quarterly basis. Modifications in rates of interest impact the reasonable worth of these instruments, with greater rates lowering their appraisal and vice versa.

Influence On Financial Results

The assessment of monetary derivatives moved from a gain of SAR 14.2 million in Q3 2025 to a loss of SAR 81.9 million in Q3 2026. For the very first 9 months of 2026, motions in acquired appraisals represented SAR 150.7 countless the SAR 170.7 million decrease in reported net earnings compared to the matching duration of 2025. The staying SAR 20.0 million was attributable to extra devaluation and ramp-up expenses connected with the Company’s continuous development and growth stage.

The following table highlights the effect of acquired evaluations on the Company’s reported and changed net revenue:

Changed net earnings is specified as reported net earnings omitting non-cash gains or losses emerging from the mark-to-market evaluation of acquired monetary instruments. This non-IFRS procedure is planned to supply extra presence into the Company’s underlying monetary efficiency, omitting the effect of variations in acquired evaluations.

Non-Cash Accounting Impact

Almoosa Health highlighted that the acquired appraisal loss is a non-cash accounting product and does not impact the Company’s money position for the reporting duration or its capability to fund continuous operations and growth strategies.

The Company discussed that the majority of the documented loss represents an accounting quote of future payments acknowledged in the present reporting duration, instead of a real money outflow throughout the quarter. The appraisal of these instruments changes with modifications in market interest rates. Appropriately, part of the documented loss might reverse in future reporting durations if rate of interest decrease and go back to the pertinent varieties, as experienced in previous durations.

Core Business Remains Profitable

Almoosa Health continued to provide development in its core health care service in Q3 2026, with profits increasing by 13.2% year-on-year to SAR 403.6 million, EBITDA increasing by 14.6% to SAR 91.4 million and operating earnings growing by 16.2% to SAR 64.6 million. EBITDA and operating earnings margins reached 22.6% and 16.0%, respectively.

This efficiency was supported by a 28.6% boost in overall client volumes compared to the very same quarter in 2015, the ongoing ramp-up of medical centers, and the growing contribution of the Company’s incorporated health care network. Drug store profits likewise increased by 14.5%, while rehab earnings grew by 23.0% compared to the exact same quarter in 2015.

Leaving out gains and losses developing from the assessment of acquired monetary instruments, net earnings totaled up to SAR 50.1 million for the quarter, representing a margin of 12.4%, and SAR 134.5 million for the very first 9 months of the year. The non-cash appraisal loss has no influence on client services, medical facility operations or the Company’s continuous development and growth strategies, which continue as prepared. Almoosa Health stays concentrated on providing premium care, enhancing running performance and structure long-lasting worth for investors.

Handling Strategy and Financial Reporting

Almoosa Health discussed that the acquired agreements were initially participated in as part of its technique to handle funding expenses. Management continues to keep track of these instruments carefully and means to report adjusted net revenue along with its statutory monetary outcomes, supplying investors with higher presence into the efficiency of the Company’s underlying organization.

Footnote: Adjusted net revenue leaves out gains and losses on acquired monetary instruments and is not an IFRS step. This summary includes positive declarations; real outcomes might vary depending upon interest-rate motions outside the Company’s control.